{"context":{"query":">>efo>>gwas_study","source_dataset":"efo","target_dataset":"gwas_study"},"stats":{"queried":1,"total":85,"mapped":1},"pagination":{"has_next":false},"schema":"id|disease_trait|first_author|journal|publication_date","mappings":[{"input":"EFO:0000676","source":"EFO:0000676|psoriasis","targets":["GCST000165|Psoriasis|Capon F|Hum Mol Genet|2008-03-25","GCST000173|Psoriasis|Liu Y|PLoS Genet|2008-04-04","GCST000321|Psoriasis|Zhang XJ|Nat Genet|2009-01-25","GCST000322|Psoriasis|Nair RP|Nat Genet|2009-01-25","GCST000833|Psoriasis|Strange A|Nat Genet|2010-10-17","GCST000834|Psoriasis|Stuart PE|Nat Genet|2010-10-17","GCST000836|Psoriasis|Ellinghaus E|Nat Genet|2010-10-17","GCST001473|Crohn's disease and psoriasis|Ellinghaus D|Am J Hum Genet|2012-04-06","GCST002738|Psoriasis|Baurecht H|Am J Hum Genet|2015-01-08","GCST002874|Psoriasis|Yin X|Nat Commun|2015-04-23","GCST002889|Psoriasis|Tsoi LC|Nat Commun|2015-05-05","GCST003097|Pediatric autoimmune diseases|Li YR|Nat Med|2015-08-24","GCST003269|Cutaneous psoriasis|Stuart PE|Am J Hum Genet|2015-11-28","GCST003271|Psoriatic arthritis vs Cutaneous psoriasis|Stuart PE|Am J Hum Genet|2015-11-28","GCST004346|Psoriasis|Tsoi LC|Nat Commun|2017-05-24","GCST005319|Frontotemporal dementia and immune-mediated diseases (pleiotropy)|Broce I|PLoS Med|2018-01-09","GCST005320|Progressive supranuclear palsy and immune-mediated diseases (pleiotropy)|Broce I|PLoS Med|2018-01-09","GCST005321|Amyotrophic lateral sclerosis and immune-mediated diseases (pleiotropy)|Broce I|PLoS Med|2018-01-09","GCST005322|Corticobasal degeneration and immune-mediated diseases (pleiotropy)|Broce I|PLoS Med|2018-01-09","GCST005527|Psoriasis|Tsoi LC|Nat Genet|2012-12-01","GCST005537|Chronic inflammatory diseases (ankylosing spondylitis, Crohn's disease, psoriasis, primary sclerosing cholangitis, ulcerative colitis) (pleiotropy)|Ellinghaus D|Nat Genet|2016-03-14","GCST005563|Primary sclerosing cholangitis associated immune-mediated diseases (Crohn's disease, celiac disease, psoriasis, rheumatoid arthritis, sarcoidosis, type 1 diabetes or ulcerative colitis) (pleiotropy)|Liu JZ|Nat Genet|2013-06-01","GCST007023|Psoriasis|Lee KY|Sci Rep|2018-10-12","GCST008096|Psoriasis|Bejaoui Y|Exp Dermatol|2019-03-28","GCST008479|Psoriasis|Zuo X|Nat Commun|2015-04-09","GCST008910|Multiple traits (pleiotropy)|Trochet H|Genet Epidemiol|2019-03-28","GCST011109|Psoriasis|Yang C|J Invest Dermatol|2019-07-31","GCST011477|COVID-19 or psoriasis (trans-disease meta-analysis)|Patrick MT|J Allergy Clin Immunol|2021-01-21","GCST011990|Psoriasis or type 2 diabetes (trans-disease meta-analysis)(opposite effect)|Patrick MT|J Invest Dermatol|2020-12-29","GCST011991|Psoriasis or type 2 diabetes (trans-disease meta-analysis)|Patrick MT|J Invest Dermatol|2020-12-29","GCST90013885|Psoriasis (Firth correction)|Mbatchou J|Nat Genet|2021-05-20","GCST90013935|Psoriasis (SPA correction)|Mbatchou J|Nat Genet|2021-05-20","GCST90014456|Psoriasis|Glanville KP|Biol Psychiatry Glob Open Sci|2021-06-01","GCST90014457|Psoriasis|Glanville KP|Biol Psychiatry Glob Open Sci|2021-06-01","GCST90019015|Psoriasis|Stuart PE|HGG Adv|2021-11-06","GCST90019016|Psoriasis|Stuart PE|HGG Adv|2021-11-06","GCST90019017|Psoriasis|Stuart PE|HGG Adv|2021-11-06","GCST90038681|Psoriasis|Donertas HM|Nat Aging|2021-04-08","GCST90044517|Psoriasis (PheCode 696.4)|Jiang L|Nat Genet|2021-11-04","GCST90077855|Psoriasis|Backman JD|Nature|2021-10-18","GCST90077856|ICD10 L40: Psoriasis|Backman JD|Nature|2021-10-18","GCST90080347|ICD10 L40.5: Arthropathic psoriasis|Backman JD|Nature|2021-10-18","GCST90080348|ICD10 L40.9: Psoriasis, unspecified|Backman JD|Nature|2021-10-18","GCST90080349|ICD10 L40: Psoriasis|Backman JD|Nature|2021-10-18","GCST90081841|Psoriasis (Gene-based burden)|Backman JD|Nature|2021-10-18","GCST90081842|ICD10 L40: Psoriasis (Gene-based burden)|Backman JD|Nature|2021-10-18","GCST90084333|ICD10 L40.5: Arthropathic psoriasis (Gene-based burden)|Backman JD|Nature|2021-10-18","GCST90084334|ICD10 L40.9: Psoriasis, unspecified (Gene-based burden)|Backman JD|Nature|2021-10-18","GCST90084335|ICD10 L40: Psoriasis (Gene-based burden)|Backman JD|Nature|2021-10-18","GCST90103418|Source of report of L40 (psoriasis) (UKB data field 131743)|Fitzgerald T|Cell Genom|2022-08-10","GCST90243957|Psoriatic arthritis vs Cutaneous psoriasis|Soomro M|Arthritis Rheumatol|2022-05-04","GCST90244705|Psoriasis or coronary artery disease|Patrick MT|Nat Commun|2022-11-02","GCST90297586|ICD10 L40: psoriasis (CNV mirror model)|Auwerx C|Genome Med|2024-01-08","GCST90297640|ICD10 L40: psoriasis (CNV U-shape model)|Auwerx C|Genome Med|2024-01-08","GCST90297691|ICD10 L40: psoriasis (CNV duplication-only model)|Auwerx C|Genome Med|2024-01-08","GCST90435157|Extraintestinal manifestations in inflammatory bowel disease (Psoriasis)|Khrom M|Gastroenterology|2024-02-27","GCST90435379|Psoriasis|Heikkila A|J Invest Dermatol|2024-05-17","GCST90435380|Psoriasis|Yang JS|Mol Med Rep|2024-05-17","GCST90435419|Insomnia or psoriasis (pleiotropy)|Wang Q|Arch Dermatol Res|2024-06-21","GCST90436606|Psoriasis and related disorders (PheCode 696)|Zhou W|Nat Genet|2018-08-13","GCST90436607|Psoriasis (PheCode 696.4)|Zhou W|Nat Genet|2018-08-13","GCST90454276|Psoriasis|Zeng Y|Am J Psychiatry|2023-04-01","GCST90468147|Psoriasis|Loya H|Nat Genet|2025-01-09","GCST90472771|Psoriasis|Dand N|Nat Commun|2025-02-28","GCST90473937|ICD10 L40: Psoriasis|UK Biobank Whole-Genome Sequencing Consortium|Nature|2025-08-06","GCST90473938|ICD10 L40: Psoriasis|UK Biobank Whole-Genome Sequencing Consortium|Nature|2025-08-06","GCST90476185|Psoriasis and related disorder (PheCode 696)|Verma A|Science|2024-07-19","GCST90476186|Psoriasis and related disorder (PheCode 696)|Verma A|Science|2024-07-19","GCST90476187|Psoriasis (PheCode 696.4)|Verma A|Science|2024-07-19","GCST90478799|Psoriasis and related disorder (PheCode 696)|Verma A|Science|2024-07-19","GCST90478800|Psoriasis (PheCode 696.4)|Verma A|Science|2024-07-19","GCST90478801|Psoriasis (PheCode 696.4)|Verma A|Science|2024-07-19","GCST90480460|Psoriasis (PheCode 696.4)|Verma A|Science|2024-07-19","GCST90480461|Psoriasis and related disorder (PheCode 696)|Verma A|Science|2024-07-19","GCST90482341|Psoriasis and related disorder (PheCode 696)|Verma A|Science|2024-07-19","GCST90482344|Psoriasis (PheCode 696.4)|Verma A|Science|2024-07-19","GCST90558096|Psoriasis|Shigesi N|Hum Reprod|2025-04-22","GCST90558097|Psoriasis|Shigesi N|Hum Reprod|2025-04-22","GCST90565134|Psoriasis|Zhang M|J Transl Med|2025-01-30","GCST90624214|Psoriasis|Liu S|Brief Bioinform|2024-11-01","GCST90624455|Palmoplantar pustulosis|Hernandez-Cordero A|J Allergy Clin Immunol|2024-05-28","GCST90651173|Psoriasis and related disorders (PheCode 696)|Liu TY|Sci Adv|2025-06-04","GCST90651179|Psoriasis (PheCode 696.4)|Liu TY|Sci Adv|2025-06-04","GCST90667842|ICD10 L40: Psoriasis|UK Biobank Whole-Genome Sequencing Consortium|Nature|2025-08-06","GCST90671996|Severe psoriasis|Saklatvala JR|Genome Med|2025-12-17"]}]}